// App-Quantinova.ai

: A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Researchers

Presenter

  • Farheen Mir

Principal Investigators

  • Andrew Grigg

  • Michael Herold

  • Wolfgang Hiddemann

  • Robert Marcus

  • John F. Seymour

  • Christopher R Bolen

  • Andrea Knapp

  • Aino Launonen

  • Federico Mattiello

  • Tina Nielsen

  • Mikkel Z Oestergaard

  • Michael Wenger

  • Carla Casulo

Medical Centers

  • Austin Hospital, Melbourne, VIC, Australia

  • HELIOS Klinikum Erfurt GmbH, Erfurt, Germany

  • Laboratory for Leukemia Diagnostics,Department of Medicine III, University Hospital, LMU Munich,Munich,Deutschland

  • Kings College London, London, United Kingdom

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Wilmot Cancer Center, Rochester, NY

Locations

  • United Kingdom

  • Australia

  • Germany

  • United States

  • Switzerland

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Bendamustine

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01332968

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved